Evidence map›Paper›PMID 32904875›Full record

ReviewCurrent transplantation reports2020

Amplifying the Patient Voice: Key Priorities and Opportunities for Improved Transplant and Living Donor Advocacy and Outcomes During COVID-19 and Beyond.

Amy D Waterman, Jim Gleason, Louise Lerminiaux, Emily H Wood, Alexander Berrios, Laurie A Meacham, Anne Osuji, Rachyl Pines, John D Peipert

Abstract readReview
In one paragraph

Review in Current transplantation reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. COVID-19 and education: restructuring after the pandemic.Transplant international : official journal of the European Society for Organ Transplantation · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amy D WatermanDivision of Nephrology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA USA.ORCID https://orcid.org/0000-0002-7799-0060
Jim GleasonTransplant Recipients International, Beverly, NJ USA.
Louise LerminiauxTransplant Diagnostics, Thermo Fisher Scientific, Los Angeles, CA USA.
Emily H WoodDivision of Nephrology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA USA.ORCID https://orcid.org/0000-0002-7141-4732
Alexander BerriosTerasaki Institute for Biomedical Innovation, University of California Los Angeles, Los Angeles, CA USA.
Laurie A MeachamTerasaki Institute for Biomedical Innovation, University of California Los Angeles, Los Angeles, CA USA.
Anne OsujiTerasaki Institute for Biomedical Innovation, University of California Los Angeles, Los Angeles, CA USA.
Rachyl PinesTerasaki Institute for Biomedical Innovation, University of California Los Angeles, Los Angeles, CA USA.ORCID https://orcid.org/0000-0002-7847-4666
John D PeipertDepartment of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL USA.ORCID https://orcid.org/0000-0001-5762-7881

Funding

TAILORED COMPUTER EDUCATION TO INCREASE LIVING DONATION IN AFRICAN-AMERICANSR01DK088711 · NIDDK · WASHINGTON UNIVERSITY · PI WATERMAN, AMY DOGGETTE · 2011 to 2015
$2.5M
NIDDK NIH HHS R01 DK088711
6 · The paper itself

Abstract

purpose of reviewTo define patient advocacy and engagement for modern transplant and living donation care, particularly in light of the COVID-19 pandemic, describe the patient experience when transplant advocacy and engagement are optimized, and recommend opportunities for advocacy within three key areas: (1) including the patient voice in healthcare decisions and drug development, (2) access to the best evidence-based treatments and informed decision-making, and (3) present and future care innovations and policies. RECENT

findingsThere are many avenues for transplant and living donation advocacy and engagement at the patient, provider, family, system, community, and policy levels. Key recommendations include the following: (1) simplifying education to be health literate, written at the appropriate reading level, culturally sensitive, and available in multiple languages and across many delivery platforms, (2) inviting transplant patients and donors to the conversation through advisory panels, consensus conferences, and new mediums like digital storytelling and patient-reported outcomes (PROs), (3) training all members of the health team to understand their role as advocates, and (4) advancing policies and programs that support the financial neutrality of living donation, and support recipients with the cost of immunosuppressive drugs. Key recommendations specific to the COVID-19 pandemic include providing up-to-date, health literate, concise information about preventing COVID-19 and accessing care including telehealth. SUMMARY: Enhancing advocacy and engagement for transplant patients and donors along the pre-to-post transplant/donation continuum can improve clinical outcomes and quality of life generally, and more so, in light of the COVID-19 pandemic.

Indexed as

COVID-19Living donationPatient advocacyPatient educationPatient engagementTransplant

Identifiers

PMID32904875
PMCPMC7462355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.